Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Bristol-Myers Squibb/Otsuka’s Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed... Learn More
Recorded live on December 10, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
This exciting one-day seminar provides attendees with a unique opportunity to hear in-depth analysis of hot topics and trends concerning global biosimilars while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
November 24, 2014
Surveyed European Oncologists Indicate that Predictive Biomarkers that Identify Patients Most Likely to Respond to Therapies Are a Clear Advantage for Costly Oncology Drugs
U.S. Claims Data Show That Biogen Idec’s Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients
November 20, 2014
Allergan’s Semprana and CoLucid’s Lasmiditan, Two Novel Acute Migraine Therapies, Will Drive Market Growth Through 2023
November 18, 2014
Zytiga is Currently the Most Commonly Prescribed Second-Line Therapy for Metastatic Castrate-Resistant Prostate Cancer, According to Surveyed European Oncologists
Emerging Market Special Report: Hepatitis C Virus in Brazil
Prevalence of the hepatitis C virus (HCV) in Brazil is estimated to be among the highest in the world; in addition, the... Read More
Treatment Algorithms in Atrial Fibrillation
For the estimated 4.6 million people in the United States who suffer from atrial fibrillation (AF), several treatment... Read More
Italy: Commercialization Outlook
Insight Accelerators are part of our Market Access Tracker service. In addition to the in-depth coverage provided in... Read More